Table 3.
Association of SII with prognosis (overall survival) in the whole study population
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age (years) | ||||
| < 65 | – | 0.003 | – | 0.018 |
| ≥ 65 | 1.699 (1.197–2.410) | 1.540 (1.077–2.202) | ||
| Gender | ||||
| Male | – | 0.484 | ||
| Female | 1.128 (0.805–1.579) | |||
| Histologic grade | ||||
| Mod/well differentiated | – | 0.245 | ||
| Poorly differentiated | 1.147 (0.910–1.446) | |||
| Primary site | ||||
| Colon | – | 0.025 | – | 0.078 |
| Rectum | 0.634 (0.426–0.944) | 0.685 (0.450–1.043) | ||
| T-stage | ||||
| T1–3 | – | 0.005 | – | 0.002 |
| T4 | 1.579 (1.149–2.169) | 1.669 (1.203–2.316) | ||
| LN status | ||||
| pN0 | – | 0.006 | – | 0.028 |
| pN+ | 1.762 (1.178–2.635) | 1.571 (1.049–2.352) | ||
| MMR status | ||||
| dMMR | – | 0.054 | ||
| pMMR | 2.415 (0.986–5.916) | |||
| Adjuvant chemotherapy | ||||
| Negative | – | 0.015 | – | 0.011 |
| Positive | 0.625 (0.429–0.912) | 0.602 (0.406–0.892) | ||
| Metastasectomy | ||||
| − | – | < 0.001 | – | 0.004 |
| + | 0.380 (0.231–0.624) | 0.479 (0.289–0.795) | ||
| Metastatic sites | ||||
| Liver | – | 0.705 | ||
| Extrahepatic disease | 0.937 (0.670–1.312) | |||
| No. of metastatic organs | ||||
| Single | – | 0.008 | – | 0.010 |
| Multiple | 1.350 (1.080–1.688) | 1.361 (1.076–1.721) | ||
| SII | ||||
| Low | – | 0.009 | – | 0.025 |
| High | 1.548 (1.116–2.146) | 1.462 (1.049–2.038) | ||
SII systemic immune-inflammation index, CI confidence interval, HR hazard ratio, LN lymph node